达安基因(002030) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥2,659,768,271.81, representing a 23.46% increase year-over-year[5] - Net profit attributable to shareholders was ¥1,316,279,924.14, up 42.04% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥1,313,690,375.07, reflecting a 40.70% increase year-over-year[5] - Basic earnings per share for the period were ¥0.9379, a 42.04% increase year-over-year[5] - The company reported a comprehensive diluted earnings per share of ¥3.4991 based on the latest share capital[9] - The net profit for the period increased, leading to a 118.10% rise in income tax expenses to ¥951,386,510.73[21] - The net profit for the current period is 4,924,221,013.32 CNY, compared to 2,543,092,652.35 CNY in the previous period, representing an increase of approximately 93.5%[45] - The total revenue from operating activities reached 7,507,873,587.22 CNY, up from 4,933,555,068.47 CNY, indicating a growth of about 52.5% year-over-year[49] - The operating profit for the current period is 5,878,332,476.13 CNY, compared to 2,980,781,298.31 CNY in the previous period, reflecting an increase of approximately 97.5%[45] - The total comprehensive income for the current period is 4,927,148,591.01 CNY, compared to 2,542,869,045.49 CNY in the previous period, indicating an increase of about 93.5%[48] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥13,848,560,585.39, a 33.98% increase from the end of the previous year[8] - Shareholders' equity attributable to the parent company reached ¥10,843,973,419.93, marking a 47.51% increase compared to the previous year[8] - Total current assets reached RMB 8,310,729,983.48, up from RMB 5,984,980,388.61, indicating a growth of about 38.7%[33] - The company's total equity reached ¥11,155,577,160.70, up from ¥7,659,969,949.39, marking an increase of approximately 45.3%[39] - Total liabilities rose to ¥2,692,983,424.69 compared to ¥2,676,474,181.92, showing a slight increase of about 0.6%[39] - The current liabilities totaled ¥2,569,874,353.01, slightly up from ¥2,521,043,571.04, indicating an increase of approximately 1.4%[39] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥2,878,155,081.97, an increase of 32.41% compared to the same period last year[5] - The cash flow from operating activities generated a net amount of 2,878,155,081.97 CNY, compared to 2,173,722,019.97 CNY in the previous period, showing an increase of about 32.4%[52] - The cash inflow from investment activities totaled 1,551,671,841.27 CNY, compared to 1,762,453,217.57 CNY in the previous period, reflecting a decrease of about 11.9%[52] - The cash outflow for purchasing fixed assets and intangible assets was 1,021,454,509.91 CNY, compared to 265,257,798.79 CNY in the previous period, indicating a significant increase in capital expenditure[52] - The company did not report any net increase in borrowing from other financial institutions during the current period[52] Investments and R&D - R&D expenses rose by 59.11% to ¥431,499,051.61, indicating increased investment in innovation[18] - Investment income increased by 69.26% to ¥240,889,914.17, primarily due to the sale of a portion of equity in YunKang Group[21] - The company has plans for market expansion and new product development, as indicated by recent announcements regarding medical device certifications[30] Market and Operational Insights - Revenue for the first nine months of 2022 reached ¥9,335,814,909.05, a 65.61% increase compared to ¥5,637,145,611.28 in the same period of 2021, driven by sustained demand for COVID-19 testing kits and related equipment[18] - Operating costs increased by 67.29% to ¥2,385,604,623.18, reflecting higher sales volume[18] - The company has obtained multiple medical device registration certificates, enhancing its product portfolio and market presence[30] - The company’s undistributed profits grew by 72.53% to ¥7,975,816,837.58, reflecting accumulated operational gains[17] Foreign Exchange and Other Comprehensive Income - The company experienced a 478.55% increase in other comprehensive income, reaching ¥2,866,443.52, due to exchange rate fluctuations[17] - The company reported a foreign currency translation difference of 2,370,992.91 CNY, compared to -148,268.44 CNY in the previous period, showing a significant recovery[48] - The impact of exchange rate changes on cash and cash equivalents was $34.24 million, contrasting with a negative impact of $279.67 thousand previously[55] Audit and Reporting - The third quarter report was not audited[56]